Time to next treatment and PFS2

Despite the high percentage of patients in Kd who received anti-CD38 in further anti-myeloma therapy, benefit with Isa-Kd over Kd was maintained late through PFS2 with a HR of 0.68 (95% CI: 0.50–0.94) (Fig. 